サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1344523

線維筋痛症治療市場：薬剤クラス別、流通チャネル別：世界の機会分析と産業予測、2023-2032年

Fibromyalgia Treatment Market By Drug Class, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日: | 発行: Allied Market Research | ページ情報: 英文 233 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
線維筋痛症治療市場：薬剤クラス別、流通チャネル別：世界の機会分析と産業予測、2023-2032年
出版日: 2023年05月30日
発行: Allied Market Research
ページ情報: 英文 233 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Allied Market Researchが発行した最新調査レポートによると、線維筋痛症治療市場は製薬セクターの市場需要増加により、2023-2032年に4.0％の大幅な成長率が見込まれています。

Fibromyalgia Treatment Market-IMG1

線維筋痛症は、身体の様々な部位における広範な筋骨格系の痛み、疲労、圧痛を特徴とする慢性疾患です。その正確な原因はよく分かっておらず、線維筋痛症の決定的な診断テストもないため、複雑な疾患と考えられています。線維筋痛症の主な症状は、筋肉、関節、軟部組織などの体の一部に影響を及ぼす慢性疼痛です。痛みは、鈍い痛み、灼熱感、深い筋肉痛などと表現されます。多くの場合、疲労、睡眠障害、認知障害、気分障害、触覚過敏などの症状を伴う。線維筋痛症の人は、痛みを強く感じたり、他の人では通常痛みや不快感を引き起こさないような刺激に反応して痛みを感じたりすることがあります。

線維筋痛症は、中枢神経系、神経伝達物質、および痛みの信号が脳内で処理される方法の間の複雑な相互作用が関与しています。線維筋痛症を確定診断できる特定の臨床検査や画像検査がないため、線維筋痛症の診断は困難です。線維筋痛症の治療は、睡眠を改善し、健康的な食事と運動を維持することに加え、症状を緩和する薬を使用することにより、症状を管理し、生活の質を改善することに重点を置いています。

世界の線維筋痛症治療市場の成長は、線維筋痛症の憂慮すべき有病率の上昇が主な要因です。全米線維筋痛症協会（2023年）によると、線維筋痛症は米国で推定1,000万人が罹患しており、有病率は75～90％と主に女性に見られます。さらに、線維筋痛症は中高年に多くみられます。世界人口の高齢化が進むにつれて、線維筋痛症を発症するリスクのある人の数は増加し、治療を必要とする患者数が増えることになります。したがって、線維筋痛症の有病率の上昇は、効果的な治療薬に対する需要を押し上げ、ひいては市場の成長を促進します。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 影響要因
    • 主な投資機会
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
      • 人口における線維筋痛症の有病率の高さ
      • 線維筋痛症およびその治療に関する認知度の急上昇
      • 線維筋痛症治療のためのジェネリック医薬品へのアクセスの向上
    • 抑制要因
      • 代替治療オプションの利用可能性
      • 発展途上国における線維筋痛症に対する認識の欠如
    • 機会
      • 線維筋痛症治療の強固なパイプライン
  • COVID-19による市場への影響分析

第4章 線維筋痛症治療市場：薬剤クラス別

  • 抗うつ薬
  • 抗痙攣薬
  • 筋弛緩薬
  • その他

第5章 線維筋痛症治療市場：流通チャネル別

  • 病院薬局
  • ドラッグストアおよび小売薬局
  • オンラインプロバイダー

第6章 線維筋痛症治療市場：地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他欧州
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカ・中東・アフリカ
    • ブラジル
    • サウジアラビア
    • 南アフリカ
    • その他の地域

第7章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング、2022年

第8章 企業プロファイル

  • Abbott Laboratories
  • Amneal Pharmaceuticals LLC
  • Eli Lilly and Company
  • Lupin Limited.
  • Novartis AG
  • Viatris Inc.
  • Zydus Lifesciences Limited
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie Inc.
図表

LIST OF TABLES

  • TABLE 01. GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 02. FIBROMYALGIA TREATMENT MARKET FOR ANTIDEPRESSANTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. FIBROMYALGIA TREATMENT MARKET FOR ANTICONVULSANTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. FIBROMYALGIA TREATMENT MARKET FOR MUSCLE RELAXANTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. FIBROMYALGIA TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 07. FIBROMYALGIA TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. FIBROMYALGIA TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. FIBROMYALGIA TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. FIBROMYALGIA TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. NORTH AMERICA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 12. NORTH AMERICA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA FIBROMYALGIA TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 14. U.S. FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 15. U.S. FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 16. CANADA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 17. CANADA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 18. MEXICO FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 19. MEXICO FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 20. EUROPE FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 21. EUROPE FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 22. EUROPE FIBROMYALGIA TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 23. GERMANY FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 24. GERMANY FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 25. FRANCE FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 26. FRANCE FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 27. UK FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 28. UK FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 29. ITALY FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 30. ITALY FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 31. SPAIN FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 32. SPAIN FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 33. REST OF EUROPE FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 34. REST OF EUROPE FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 35. ASIA-PACIFIC FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 36. ASIA-PACIFIC FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 37. ASIA-PACIFIC FIBROMYALGIA TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 38. JAPAN FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 39. JAPAN FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 40. CHINA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 41. CHINA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 42. INDIA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 43. INDIA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 44. AUSTRALIA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 45. AUSTRALIA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 46. SOUTH KOREA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 47. SOUTH KOREA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 48. REST OF ASIA-PACIFIC FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 49. REST OF ASIA-PACIFIC FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 50. LAMEA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 51. LAMEA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 52. LAMEA FIBROMYALGIA TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 53. BRAZIL FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 54. BRAZIL FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 55. SAUDI ARABIA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 56. SAUDI ARABIA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 57. SOUTH AFRICA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 58. SOUTH AFRICA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 59. REST OF LAMEA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 60. REST OF LAMEA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 61. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 62. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 63. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 64. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 65. AMNEAL PHARMACEUTICALS LLC: KEY EXECUTIVES
  • TABLE 66. AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT
  • TABLE 67. AMNEAL PHARMACEUTICALS LLC: PRODUCT SEGMENTS
  • TABLE 68. AMNEAL PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
  • TABLE 69. AMNEAL PHARMACEUTICALS LLC: KEY STRATERGIES
  • TABLE 70. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 71. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 72. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
  • TABLE 73. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 74. LUPIN LIMITED.: KEY EXECUTIVES
  • TABLE 75. LUPIN LIMITED.: COMPANY SNAPSHOT
  • TABLE 76. LUPIN LIMITED.: PRODUCT SEGMENTS
  • TABLE 77. LUPIN LIMITED.: PRODUCT PORTFOLIO
  • TABLE 78. LUPIN LIMITED.: KEY STRATERGIES
  • TABLE 79. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 80. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 81. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 82. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 83. NOVARTIS AG: KEY STRATERGIES
  • TABLE 84. VIATRIS INC.: KEY EXECUTIVES
  • TABLE 85. VIATRIS INC.: COMPANY SNAPSHOT
  • TABLE 86. VIATRIS INC.: PRODUCT SEGMENTS
  • TABLE 87. VIATRIS INC.: PRODUCT PORTFOLIO
  • TABLE 88. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
  • TABLE 89. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
  • TABLE 90. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
  • TABLE 91. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
  • TABLE 92. ZYDUS LIFESCIENCES LIMITED: KEY STRATERGIES
  • TABLE 93. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 94. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 95. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
  • TABLE 96. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 97. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 98. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 99. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 100. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 101. ABBVIE INC.: KEY EXECUTIVES
  • TABLE 102. ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 103. ABBVIE INC.: PRODUCT SEGMENTS
  • TABLE 104. ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 105. ABBVIE INC.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. FIBROMYALGIA TREATMENT MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF FIBROMYALGIA TREATMENT MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN FIBROMYALGIA TREATMENT MARKET (2023-2032)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALFIBROMYALGIA TREATMENT MARKET
  • FIGURE 10. FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF FIBROMYALGIA TREATMENT MARKET FOR ANTIDEPRESSANTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF FIBROMYALGIA TREATMENT MARKET FOR ANTICONVULSANTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF FIBROMYALGIA TREATMENT MARKET FOR MUSCLE RELAXANTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF FIBROMYALGIA TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF FIBROMYALGIA TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF FIBROMYALGIA TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF FIBROMYALGIA TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. FIBROMYALGIA TREATMENT MARKET BY REGION, 2022
  • FIGURE 20. U.S. FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 21. CANADA FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 22. MEXICO FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. GERMANY FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. FRANCE FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. UK FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. ITALY FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. SPAIN FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. REST OF EUROPE FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. JAPAN FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. CHINA FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. INDIA FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. AUSTRALIA FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. SOUTH KOREA FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. REST OF ASIA-PACIFIC FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. BRAZIL FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. SAUDI ARABIA FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. SOUTH AFRICA FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. REST OF LAMEA FIBROMYALGIA TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 40. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 41. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 42. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 43. COMPETITIVE DASHBOARD
  • FIGURE 44. COMPETITIVE HEATMAP: FIBROMYALGIA TREATMENT MARKET
  • FIGURE 45. TOP PLAYER POSITIONING, 2022
  • FIGURE 46. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 48. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 49. AMNEAL PHARMACEUTICALS LLC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 50. AMNEAL PHARMACEUTICALS LLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 51. ELI LILLY AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 52. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 53. LUPIN LIMITED.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. LUPIN LIMITED.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 55. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 57. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 58. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 60. ZYDUS LIFESCIENCES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 61. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 62. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 63. SUN PHARMACEUTICAL INDUSTRIES LIMITED: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 64. SUN PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 65. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 66. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 67. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 68. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 69. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)
目次
Product Code: A13357

The fibromyalgia treatment market is likely to experience a significant growth rate of 4.0% from 2023-2032 owing to increasing market demand from pharmaceutical sector - Allied Market Research

Fibromyalgia Treatment Market - IMG1

Fibromyalgia is a chronic disorder characterized by widespread musculoskeletal pain, fatigue, and tenderness in various parts of the body. It is considered as a complex condition because its exact cause is not well understood, and there is no definitive diagnostic test for fibromyalgia. The primary symptom of fibromyalgia is chronic pain that affects body parts such as muscles, joints, and soft tissues. The pain may be described as a dull ache, a burning sensation, or a deep muscular soreness. It is often accompanied by other symptoms such as fatigue, sleep disturbances, cognitive difficulties, mood disorders, and heightened sensitivity to touch. People with fibromyalgia may experience pain more intensely or feel pain in response to stimuli that would not typically cause pain or discomfort in others.

It involves a complex interaction between the central nervous system, neurotransmitters, and the way pain signals are processed in the brain. Diagnosing fibromyalgia can be challenging as there are no specific laboratory tests or imaging studies that can definitively confirm the condition. Treatment for fibromyalgia focuses on managing symptoms and improving quality of life by using medications to alleviate the symptoms along with improving sleep and maintaining a healthy diet and exercise.

The growth of the global fibromyalgia treatment market is majorly driven by alarming rise in prevalence of fibromyalgia. According to the National Fibromyalgia Association (2023), fibromyalgia affects an estimated 10 million people in the U.S. and is mostly seen among women, with a prevalence of 75-90%. Moreover, fibromyalgia is more commonly diagnosed in middle-aged and older individuals. As the global population continues to age, the number of people at risk for developing fibromyalgia increases, leading to a larger patient pool requiring treatment. Thus, rise in prevalence of fibromyalgia boosts the demand for effective treatment medications, which, in turn, propels the growth of the market.

In addition, surge in awareness regarding fibromyalgia and its diagnosis and treatment among the people in developed countries acts as a major driver of the global market. Improved diagnosis and awareness have played a significant role in the identification and treatment of fibromyalgia. In the past, fibromyalgia was often misunderstood or misdiagnosed, leading to delayed or ineffective treatment for many individuals.

Moreover, in past few years, healthcare professionals and the general population have increasingly acknowledged and gained a better understanding of fibromyalgia condition. For instance, diagnostic criteria for fibromyalgia have evolved and become more refined. The American College of Rheumatology (ACR) has established updated diagnostic criteria, along with other assessment tools, which have helped healthcare professionals more accurately diagnose fibromyalgia. This will further significantly contribute to the growth of the fibromyalgia treatment market.

However, in addition to conventional medical approaches, certain individuals with fibromyalgia may explore alternative treatment options to help manage their symptoms. For instance, acupuncture and other therapies may be involved which hinder the market growth to some extent.

In addition, lack of knowledge and awareness about fibromyalgia in underdeveloped countries may have a negative impact on the growth of the market. In underdeveloped countries, there may be limited healthcare infrastructure, fewer trained healthcare professionals, and lack of specialized clinics or resources dedicated to chronic pain conditions such as fibromyalgia. This contribute to lack of awareness among both healthcare providers and the general population, which acts as a key deterrent factor of the global market.

On the contrary, a robust pipeline of products for fibromyalgia treatment presents an encouraging outlook for both patients and key players in the market. The development of new medications specifically targeting fibromyalgia holds the potential to address the unmet needs of patients and improve their quality of life. Continuous research and development efforts by pharmaceutical companies, researchers, and healthcare professionals demonstrate a commitment to finding more effective and safer treatment options for fibromyalgia. This includes exploring novel therapeutic approaches and investigating potential targeted therapies. Such strategies adopted by key players are anticipated to boost market growth during the forecast period.

In addition, emerging countries in Asia-Pacific and LAMEA present lucrative opportunities for key players looking to invest in the fibromyalgia treatment market. This is attributed to the fact that these regions are characterized by the presence of a large population base with notable economic growth and increase in healthcare expenditure. In addition, an alarming rise in prevalence of fibromyalgia in these regions along with rise in awareness about the condition is anticipated to drive the market growth.

The global fibromyalgia treatment market is segmented into drug class, distribution channel, and region. Depending on drug class, the market is categorized into antidepressants, anticonvulsants, muscle relaxants, and others. Based on distribution channel, it is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major players that operate in the market include Abbott Laboratories Abbvie Inc., Amneal Pharmaceuticals LLC, Eli Lilly and Company, Lupin, Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, Viatris Inc., and Zydus Lifesciences Limited.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the fibromyalgia treatment market analysis from 2022 to 2032 to identify the prevailing fibromyalgia treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the fibromyalgia treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global fibromyalgia treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Class

  • Antidepressants
  • Anticonvulsants
  • Muscle Relaxants
  • Others

By Distribution Channel

  • Hospital pharmacies
  • Drug stores and retail pharmacies
  • Online providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Abbott Laboratories
    • Teva Pharmaceutical Industries Ltd.
    • AbbVie Inc.
    • Amneal Pharmaceuticals LLC
    • Zydus Lifesciences Limited
    • Sun Pharmaceutical Industries Limited
    • Eli Lilly and Company
    • Novartis AG
    • Viatris Inc.
    • Lupin Limited.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Significant prevalence of fibromyalgia among the population
      • 3.4.1.2. Surge in awareness regarding fibromyalgia and its treatment
      • 3.4.1.3. Enhanced access to generic medications for fibromyalgia treatment
    • 3.4.2. Restraints
      • 3.4.2.1. Availability of alternate treatment options
      • 3.4.2.2. Lack of awareness about fibromyalgia in underdeveloped countries
    • 3.4.3. Opportunities
      • 3.4.3.1. Robust pipeline of products for fibromyalgia treatment
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Antidepressants
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Anticonvulsants
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Muscle Relaxants
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Others
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Hospital pharmacies
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Drug stores and retail pharmacies
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Online providers
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: FIBROMYALGIA TREATMENT MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast By Region
  • 6.2. North America
    • 6.2.1. Key trends and opportunities
    • 6.2.2. Market size and forecast, by Drug Class
    • 6.2.3. Market size and forecast, by Distribution Channel
    • 6.2.4. Market size and forecast, by country
      • 6.2.4.1. U.S.
      • 6.2.4.1.1. Key market trends, growth factors and opportunities
      • 6.2.4.1.2. Market size and forecast, by Drug Class
      • 6.2.4.1.3. Market size and forecast, by Distribution Channel
      • 6.2.4.2. Canada
      • 6.2.4.2.1. Key market trends, growth factors and opportunities
      • 6.2.4.2.2. Market size and forecast, by Drug Class
      • 6.2.4.2.3. Market size and forecast, by Distribution Channel
      • 6.2.4.3. Mexico
      • 6.2.4.3.1. Key market trends, growth factors and opportunities
      • 6.2.4.3.2. Market size and forecast, by Drug Class
      • 6.2.4.3.3. Market size and forecast, by Distribution Channel
  • 6.3. Europe
    • 6.3.1. Key trends and opportunities
    • 6.3.2. Market size and forecast, by Drug Class
    • 6.3.3. Market size and forecast, by Distribution Channel
    • 6.3.4. Market size and forecast, by country
      • 6.3.4.1. Germany
      • 6.3.4.1.1. Key market trends, growth factors and opportunities
      • 6.3.4.1.2. Market size and forecast, by Drug Class
      • 6.3.4.1.3. Market size and forecast, by Distribution Channel
      • 6.3.4.2. France
      • 6.3.4.2.1. Key market trends, growth factors and opportunities
      • 6.3.4.2.2. Market size and forecast, by Drug Class
      • 6.3.4.2.3. Market size and forecast, by Distribution Channel
      • 6.3.4.3. UK
      • 6.3.4.3.1. Key market trends, growth factors and opportunities
      • 6.3.4.3.2. Market size and forecast, by Drug Class
      • 6.3.4.3.3. Market size and forecast, by Distribution Channel
      • 6.3.4.4. Italy
      • 6.3.4.4.1. Key market trends, growth factors and opportunities
      • 6.3.4.4.2. Market size and forecast, by Drug Class
      • 6.3.4.4.3. Market size and forecast, by Distribution Channel
      • 6.3.4.5. Spain
      • 6.3.4.5.1. Key market trends, growth factors and opportunities
      • 6.3.4.5.2. Market size and forecast, by Drug Class
      • 6.3.4.5.3. Market size and forecast, by Distribution Channel
      • 6.3.4.6. Rest of Europe
      • 6.3.4.6.1. Key market trends, growth factors and opportunities
      • 6.3.4.6.2. Market size and forecast, by Drug Class
      • 6.3.4.6.3. Market size and forecast, by Distribution Channel
  • 6.4. Asia-Pacific
    • 6.4.1. Key trends and opportunities
    • 6.4.2. Market size and forecast, by Drug Class
    • 6.4.3. Market size and forecast, by Distribution Channel
    • 6.4.4. Market size and forecast, by country
      • 6.4.4.1. Japan
      • 6.4.4.1.1. Key market trends, growth factors and opportunities
      • 6.4.4.1.2. Market size and forecast, by Drug Class
      • 6.4.4.1.3. Market size and forecast, by Distribution Channel
      • 6.4.4.2. China
      • 6.4.4.2.1. Key market trends, growth factors and opportunities
      • 6.4.4.2.2. Market size and forecast, by Drug Class
      • 6.4.4.2.3. Market size and forecast, by Distribution Channel
      • 6.4.4.3. India
      • 6.4.4.3.1. Key market trends, growth factors and opportunities
      • 6.4.4.3.2. Market size and forecast, by Drug Class
      • 6.4.4.3.3. Market size and forecast, by Distribution Channel
      • 6.4.4.4. Australia
      • 6.4.4.4.1. Key market trends, growth factors and opportunities
      • 6.4.4.4.2. Market size and forecast, by Drug Class
      • 6.4.4.4.3. Market size and forecast, by Distribution Channel
      • 6.4.4.5. South Korea
      • 6.4.4.5.1. Key market trends, growth factors and opportunities
      • 6.4.4.5.2. Market size and forecast, by Drug Class
      • 6.4.4.5.3. Market size and forecast, by Distribution Channel
      • 6.4.4.6. Rest of Asia-Pacific
      • 6.4.4.6.1. Key market trends, growth factors and opportunities
      • 6.4.4.6.2. Market size and forecast, by Drug Class
      • 6.4.4.6.3. Market size and forecast, by Distribution Channel
  • 6.5. LAMEA
    • 6.5.1. Key trends and opportunities
    • 6.5.2. Market size and forecast, by Drug Class
    • 6.5.3. Market size and forecast, by Distribution Channel
    • 6.5.4. Market size and forecast, by country
      • 6.5.4.1. Brazil
      • 6.5.4.1.1. Key market trends, growth factors and opportunities
      • 6.5.4.1.2. Market size and forecast, by Drug Class
      • 6.5.4.1.3. Market size and forecast, by Distribution Channel
      • 6.5.4.2. Saudi Arabia
      • 6.5.4.2.1. Key market trends, growth factors and opportunities
      • 6.5.4.2.2. Market size and forecast, by Drug Class
      • 6.5.4.2.3. Market size and forecast, by Distribution Channel
      • 6.5.4.3. South Africa
      • 6.5.4.3.1. Key market trends, growth factors and opportunities
      • 6.5.4.3.2. Market size and forecast, by Drug Class
      • 6.5.4.3.3. Market size and forecast, by Distribution Channel
      • 6.5.4.4. Rest of LAMEA
      • 6.5.4.4.1. Key market trends, growth factors and opportunities
      • 6.5.4.4.2. Market size and forecast, by Drug Class
      • 6.5.4.4.3. Market size and forecast, by Distribution Channel

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

  • 8.1. Abbott Laboratories
    • 8.1.1. Company overview
    • 8.1.2. Key Executives
    • 8.1.3. Company snapshot
    • 8.1.4. Operating business segments
    • 8.1.5. Product portfolio
    • 8.1.6. Business performance
  • 8.2. Amneal Pharmaceuticals LLC
    • 8.2.1. Company overview
    • 8.2.2. Key Executives
    • 8.2.3. Company snapshot
    • 8.2.4. Operating business segments
    • 8.2.5. Product portfolio
    • 8.2.6. Business performance
    • 8.2.7. Key strategic moves and developments
  • 8.3. Eli Lilly and Company
    • 8.3.1. Company overview
    • 8.3.2. Key Executives
    • 8.3.3. Company snapshot
    • 8.3.4. Operating business segments
    • 8.3.5. Product portfolio
    • 8.3.6. Business performance
  • 8.4. Lupin Limited.
    • 8.4.1. Company overview
    • 8.4.2. Key Executives
    • 8.4.3. Company snapshot
    • 8.4.4. Operating business segments
    • 8.4.5. Product portfolio
    • 8.4.6. Business performance
    • 8.4.7. Key strategic moves and developments
  • 8.5. Novartis AG
    • 8.5.1. Company overview
    • 8.5.2. Key Executives
    • 8.5.3. Company snapshot
    • 8.5.4. Operating business segments
    • 8.5.5. Product portfolio
    • 8.5.6. Business performance
    • 8.5.7. Key strategic moves and developments
  • 8.6. Viatris Inc.
    • 8.6.1. Company overview
    • 8.6.2. Key Executives
    • 8.6.3. Company snapshot
    • 8.6.4. Operating business segments
    • 8.6.5. Product portfolio
    • 8.6.6. Business performance
  • 8.7. Zydus Lifesciences Limited
    • 8.7.1. Company overview
    • 8.7.2. Key Executives
    • 8.7.3. Company snapshot
    • 8.7.4. Operating business segments
    • 8.7.5. Product portfolio
    • 8.7.6. Business performance
    • 8.7.7. Key strategic moves and developments
  • 8.8. Sun Pharmaceutical Industries Limited
    • 8.8.1. Company overview
    • 8.8.2. Key Executives
    • 8.8.3. Company snapshot
    • 8.8.4. Operating business segments
    • 8.8.5. Product portfolio
    • 8.8.6. Business performance
  • 8.9. Teva Pharmaceutical Industries Ltd.
    • 8.9.1. Company overview
    • 8.9.2. Key Executives
    • 8.9.3. Company snapshot
    • 8.9.4. Operating business segments
    • 8.9.5. Product portfolio
    • 8.9.6. Business performance
  • 8.10. AbbVie Inc.
    • 8.10.1. Company overview
    • 8.10.2. Key Executives
    • 8.10.3. Company snapshot
    • 8.10.4. Operating business segments
    • 8.10.5. Product portfolio
    • 8.10.6. Business performance
    • 8.10.7. Key strategic moves and developments